The mechanism of action of this antitumoral peptide is not completely understood, but it seems the peptide interferes with the tyrosine kinase activity associated with the VEGF signalling axis in endothelial cells inhibiting angiogenesis processes (in vivo testing with Mat Ly Lu rat prostate cancer cells) (207) and reduces the levels of plasma matrix metalloproteinase MMP-9 (a CD44 ligand). Here, CD44 is linked to prostate carcinoma.